Friday, December 30, 2011
Pertuzumab improved PFS when given with trastuzumab, chemotherapy
SAN ANTONIO — According to data presented, patients with HER-2–positive metastatic or locally recurrent breast cancer had a longer PFS when they received a triple-drug combination that included pertuzumab, trastuzumab and docetaxel vs. patients who only received trastuzumab and docetaxel.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment